Free Trial

Bio-Rad Laboratories (BIO) Competitors

$286.86
+4.85 (+1.72%)
(As of 05/31/2024 ET)

BIO vs. MTD, WAT, ILMN, TECH, CRL, BRKR, PACB, HBIO, LIFE, and TMO

Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Harvard Bioscience (HBIO), aTyr Pharma (LIFE), and Thermo Fisher Scientific (TMO). These companies are all part of the "life sciences tools & services" industry.

Bio-Rad Laboratories vs.

Mettler-Toledo International (NYSE:MTD) and Bio-Rad Laboratories (NYSE:BIO) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking.

Mettler-Toledo International has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.79B7.92$788.78M$35.6639.37
Bio-Rad Laboratories$2.67B3.06-$637.32M-$10.36-27.69

Mettler-Toledo International has a net margin of 20.55% compared to Mettler-Toledo International's net margin of -12.37%. Mettler-Toledo International's return on equity of 3.59% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Mettler-Toledo International20.55% -662.32% 25.11%
Bio-Rad Laboratories -12.37%3.59%2.55%

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 1.9% of Mettler-Toledo International shares are owned by insiders. Comparatively, 17.1% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Mettler-Toledo International received 3 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. However, 64.94% of users gave Bio-Rad Laboratories an outperform vote while only 57.46% of users gave Mettler-Toledo International an outperform vote.

CompanyUnderperformOutperform
Mettler-Toledo InternationalOutperform Votes
366
57.46%
Underperform Votes
271
42.54%
Bio-Rad LaboratoriesOutperform Votes
363
64.94%
Underperform Votes
196
35.06%

Mettler-Toledo International has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

In the previous week, Bio-Rad Laboratories had 8 more articles in the media than Mettler-Toledo International. MarketBeat recorded 18 mentions for Bio-Rad Laboratories and 10 mentions for Mettler-Toledo International. Bio-Rad Laboratories' average media sentiment score of 1.31 beat Mettler-Toledo International's score of 0.48 indicating that Mettler-Toledo International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mettler-Toledo International
9 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bio-Rad Laboratories
6 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Mettler-Toledo International currently has a consensus target price of $1,257.14, suggesting a potential downside of 10.47%. Bio-Rad Laboratories has a consensus target price of $461.00, suggesting a potential upside of 60.71%. Given Mettler-Toledo International's stronger consensus rating and higher probable upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Mettler-Toledo International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mettler-Toledo International
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Bio-Rad Laboratories
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summary

Mettler-Toledo International beats Bio-Rad Laboratories on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIO vs. The Competition

MetricBio-Rad LaboratoriesAnalytical instruments IndustryMedical SectorNYSE Exchange
Market Cap$8.18B$5.11B$5.11B$17.81B
Dividend YieldN/A0.43%2.75%3.54%
P/E Ratio-27.6912.56117.2722.43
Price / Sales3.064.852,424.4210.50
Price / Cash23.3035.9735.0418.95
Price / Book0.902.285.525.90
Net Income-$637.32M-$10.98M$105.88M$976.46M
7 Day Performance-0.12%-1.83%1.13%0.62%
1 Month Performance4.78%-5.85%1.42%4.79%
1 Year Performance-22.75%-27.12%4.04%24.00%

Bio-Rad Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTD
Mettler-Toledo International
3.5469 of 5 stars
$1,392.81
-3.1%
$1,257.14
-9.7%
+6.2%$29.75B$3.79B39.0617,300Analyst Revision
Positive News
WAT
Waters
3.9369 of 5 stars
$312.00
-4.8%
$305.78
-2.0%
+23.0%$18.51B$2.96B30.627,900Insider Buying
Analyst Revision
ILMN
Illumina
4.694 of 5 stars
$102.19
+0.4%
$164.65
+61.1%
-47.0%$16.28B$4.50B-12.549,300Short Interest ↑
TECH
Bio-Techne
4.1331 of 5 stars
$77.55
-1.3%
$81.00
+4.4%
-5.6%$12.22B$1.14B61.553,050
CRL
Charles River Laboratories International
4.5802 of 5 stars
$211.39
0.0%
$255.27
+20.8%
+7.8%$10.89B$4.11B24.8721,800Short Interest ↓
Analyst Revision
News Coverage
BRKR
Bruker
4.944 of 5 stars
$67.24
-7.3%
$85.00
+26.4%
-5.2%$9.77B$2.96B24.459,707Short Interest ↑
High Trading Volume
PACB
Pacific Biosciences of California
3.0161 of 5 stars
$1.83
+0.5%
$6.59
+260.2%
-85.5%$498.42M$200.52M-1.61796Gap Down
HBIO
Harvard Bioscience
1.046 of 5 stars
$3.17
+2.3%
N/A-43.3%$137.67M$112.25M-15.85391Short Interest ↓
LIFE
aTyr Pharma
3.2424 of 5 stars
$1.73
+3.0%
$23.67
+1,268.0%
-23.8%$119.39M$350,000.00-1.9256Short Interest ↓
Positive News
TMO
Thermo Fisher Scientific
4.6183 of 5 stars
$559.00
-1.5%
$605.31
+8.3%
+11.7%$213.38B$42.86B35.86122,000Positive News

Related Companies and Tools

This page (NYSE:BIO) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners